Comparison of oral misoprostol versus intramuscular oxytocin for active management of third stage of labour: a single centre randomised controlled study
DOI:
https://doi.org/10.18203/2320-1770.ijrcog20230808Keywords:
Misoprostol, Oxytocin, PPH (Post partum haemorrhage), Active management of third stage of labour (AMTSL)Abstract
Background: This study was conducted to compare the efficacy and safety of oral misoprostol against intramuscular oxytocin in the active management of the third stage of labour, so that it can be widely used in the areas of limited resources to contribute in preventing post-partum haemorrhage and thus decreasing maternal mortality ratio.
Methods: This was a prospective randomised controlled clinical study. Two hundred patients fulfilling inclusion criteria were randomized to receive either oral misoprostol (600 mcg) or intramuscular oxytocin (10 IU) in the active management of third stage of labour. Primary outcome measured was mean blood loss and incidence of primary PPH.
Results: The mean blood loss during third stage of labour in oral misoprostol group and oxytocin group was 239.16±22.78 ml and 240.19±19.70 ml respectively with p value-0.7331 which was insignificant. Similarly mean fall in haemoglobin was also not significant. There was no significant differences between the two groups with regard to the incidence of PPH (3% vs. 2% respectively; p=0.651). Women experiencing side effects like shivering and fever were significantly higher among misoprostol group than in oxytocin group.
Conclusions: In this study, oral misoprostol was found to be comparable to intramuscular oxytocin regimen, in terms of amount of blood loss, occurrence of postpartum hemorrhage, duration of third stage of labour, fall in hemoglobin and fall in blood pressure. However, shivering and fever were more common with misoprostol, but no other serious side effects were noted.
References
Maternal mortality ratio (per 100 000 live births), 2015. Available at: https://www.who.int/data/ gho/indicator-metadata-registry/imr-details/26. Accessed on 7 January 2023.
Alkema L, Chou D, Hogan D, Zhang S, Moller AB, Gemmil A, et al. United Nations Maternal Mortality Estimation Inter-Agency Group collaborators and technical advisory group. Global, regional, and national levels and trends in maternal mortality between 1990 and 2015, with scenario-based projections to 2030: a systematic analysis by the UN maternal mortality estimation inter-agency group. Lancet. 2016;387(10017):462-74.
Say L, Chou D, Gemmill A, Tunçalp O, Moller AB, Daniels J, et al. Global causes of maternal death: a WHO systematic analysis. Lancet Glob Health. 2014;2(6):e323-33.
UNICEF’s concerted action to increase access to quality maternal health services, 2020. Available at: https://www.unicef.org/india/what-we-do/maternal-health. Accessed 7 January 2023.
Factsheet: The world health report: 2005: make every mother and child count, 2005. Available at: https://www.afro.who.int/sites/default/files/2017-07/whr2005_en.pdf. Accessed on 8 January 2023.
Centre for Maternal and Child Enquiries. Saving Mothers' Lives: Reviewing Maternal Deaths to Make Motherhood Safer: 2006-08. The eighth report on confidential enquiries into maternal deaths in the United Kingdom. Br J Obstet Gynaecol. 2011;118:1-203.
Konar H, Dutta DC. Complications of third stage of labor. In: Konar H editor. Text Book of Obstetrics. 9th ed. New Delhi: The Health Sciences Publisher; 2018; 2:385-96.
WHO recommendations for the prevention and treatment of postpartum hemorrhage, 2012. Available at: https://apps.who.int/iris/bitstream/handle/10665/ 75411/9789241548502_eng.pdf. Accessed on 8 January 2023.
Parsons SM, Walley RL, Crane JM, Matthews K, Hutchens D. Rectal misoprostol versus oxytocin in the management of the third stage of labour. J Obstet Gynaecol Can. 2007;29(9):711-8.
Cunningham FG, Gant NF, Cox SM, Leveno KJ, Gilstrap L, Hauth J, Wenstrom KD. Conduct of normal labor and delivery. In: Cunningham FG, Gant NF, Leveno KJ, Gilstrap LC, Hauth JC, Wenstrom KD, eds. 21st ed. Philadelphia: McGraw-Hill; 2001:309-29.
Lam H, Tang OS, Lee CP, Ho PC. A pilot-randomized comparison of sublingual misoprostol with syntometrine on the blood loss in third stage of labor. Acta Obstet Gynecol Scand. 2004;83(7):647-50.
Sanchez-Ramos L, Delke I. Induction of labor and pregnancy termination for fetal abnormality. In: James DK, Steer PJ, Weiner CP, Gonik B, eds. High Risk pregnancy management options. 3rd ed. USA: Elsevier; 2006:1392-425.
Khan RU, El-Refaey H. Pharmacokinetics and adverse-effect profile of rectally administered misoprostol in the third stage of labor. Obstet Gynecol. 2003;101(5):968-74.
Tang OS, Gemzell-Danielsson K, Ho PC. Misoprostol: pharmacokinetic profiles, effects on the uterus and side-effects. Int J Gynaecol Obstet. 2007;99(2):S160-7.
Zachariah ES, Naidu M, Seshadri L. Oral misoprostol in the third stage of labor. Int J Gynaecol Obstet. 2006; 92(1):23-6.
Subedi N, Sharma D, Das R. Comparison of misoprostol with oxytocin in third stage of labour. J Univers Coll Med Sci. 2018;6(1):19-21.
Oboro VO, Tabowei TO. A randomised controlled trial of misoprostol versus oxytocin in the active management of the third stage of labour. J Obstet Gynaecol. 2003;23(1):13-6.
Afolabi EO, Kuti O, Orji EO, Ogunniyi SO. Oral misoprostol versus intramuscular oxytocin in the active management of the third stage of labour. Singapore Med J. 2010;51(3):207-11.
Walley RL, Wilson JB, Crane JM, Matthews K, Sawyer E, Hutchens D. A double blind placebo controlled randomised trial of misoprostol and oxytocin in the management of the third stage of labour. Br J Obstet Gynecol. 2000;107(9):1111-5.
Alam A, Paresh S, Goswami S. A comparative study of efficacy of oxytocin, methylergometrine and misoprostol in prevention of post-partum haemorrhage. Int J Reprod Contracept Obstet Gynecol. 2017;6(5):1960-64.
Kaudel S, Rana A, Ojha N. Comparison of oral misoprostol with intramuscular oxytocin in the active management of third stage of labour. Nepal J Obstet Gynaecol. 2015;10(1):76-80.
